Strategic Modeling and Simulation Services for Autoimmune Disorders
Certara Strategic Consulting scientists have extensive experience in immunological disorders. We have also leveraged comparator data to support Phase 2b dose selection for the treatment of autoimmune disorders.
- Rheumatoid arthritis
- Crohn’s disease
- Systemic sclerosis
- Multiple sclerosis
Clinical trial outcomes databases
We have developed an RA Clinical Outcomes Database which serves as an enabling tool in our consulting projects as well as a stand-alone product for interested clients. In this publication, a dose-response meta-analysis was done using this database to quantify relative efficacy of biologic disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA).
In addition, we have also built a database focused on treatment for remitting relapsing multiple sclerosis.
By partnering with Certara Strategic Consulting, you can leverage the power of model-informed drug development technology to get your drug to market faster.